nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—ALB—Auranofin—psoriatic arthritis	0.15	0.332	CbGbCtD
Vandetanib—ABCC1—Methotrexate—psoriatic arthritis	0.0518	0.115	CbGbCtD
Vandetanib—ALB—Prednisone—psoriatic arthritis	0.0476	0.106	CbGbCtD
Vandetanib—ABCG2—Dexamethasone—psoriatic arthritis	0.0431	0.0958	CbGbCtD
Vandetanib—ABCG2—Methotrexate—psoriatic arthritis	0.0346	0.077	CbGbCtD
Vandetanib—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0246	0.0547	CbGbCtD
Vandetanib—ALB—Methotrexate—psoriatic arthritis	0.0239	0.0531	CbGbCtD
Vandetanib—CYP3A4—Triamcinolone—psoriatic arthritis	0.0187	0.0415	CbGbCtD
Vandetanib—CYP3A4—Betamethasone—psoriatic arthritis	0.016	0.0356	CbGbCtD
Vandetanib—CYP3A4—Prednisolone—psoriatic arthritis	0.0158	0.0351	CbGbCtD
Vandetanib—CYP3A4—Prednisone—psoriatic arthritis	0.0149	0.0332	CbGbCtD
Vandetanib—RIPK2—synovial membrane of synovial joint—psoriatic arthritis	0.013	0.161	CbGeAlD
Vandetanib—CYP3A4—Dexamethasone—psoriatic arthritis	0.00931	0.0207	CbGbCtD
Vandetanib—ORM1—vertebral column—psoriatic arthritis	0.00727	0.0905	CbGeAlD
Vandetanib—PTK6—skin of body—psoriatic arthritis	0.00433	0.0539	CbGeAlD
Vandetanib—TYRO3—skin of body—psoriatic arthritis	0.00335	0.0417	CbGeAlD
Vandetanib—STK35—skin of body—psoriatic arthritis	0.00279	0.0348	CbGeAlD
Vandetanib—RIPK2—skin of body—psoriatic arthritis	0.00257	0.0321	CbGeAlD
Vandetanib—ERBB3—skin of body—psoriatic arthritis	0.00246	0.0307	CbGeAlD
Vandetanib—AXL—skin of body—psoriatic arthritis	0.00228	0.0283	CbGeAlD
Vandetanib—FYN—skin of body—psoriatic arthritis	0.00213	0.0265	CbGeAlD
Vandetanib—STK35—tendon—psoriatic arthritis	0.00213	0.0265	CbGeAlD
Vandetanib—ABL2—tendon—psoriatic arthritis	0.00207	0.0258	CbGeAlD
Vandetanib—EPHB6—skin of body—psoriatic arthritis	0.00199	0.0248	CbGeAlD
Vandetanib—RIPK2—tendon—psoriatic arthritis	0.00196	0.0244	CbGeAlD
Vandetanib—VEGFA—tendon—psoriatic arthritis	0.00195	0.0243	CbGeAlD
Vandetanib—FMO1—tendon—psoriatic arthritis	0.00194	0.0242	CbGeAlD
Vandetanib—IRAK4—tendon—psoriatic arthritis	0.00191	0.0238	CbGeAlD
Vandetanib—SRC—skin of body—psoriatic arthritis	0.00185	0.023	CbGeAlD
Vandetanib—RET—tendon—psoriatic arthritis	0.00174	0.0217	CbGeAlD
Vandetanib—FGR—tendon—psoriatic arthritis	0.00174	0.0217	CbGeAlD
Vandetanib—AXL—tendon—psoriatic arthritis	0.00173	0.0216	CbGeAlD
Vandetanib—SLK—tendon—psoriatic arthritis	0.00167	0.0208	CbGeAlD
Vandetanib—FYN—tendon—psoriatic arthritis	0.00162	0.0202	CbGeAlD
Vandetanib—TEK—tendon—psoriatic arthritis	0.00158	0.0197	CbGeAlD
Vandetanib—MAP4K5—tendon—psoriatic arthritis	0.00158	0.0197	CbGeAlD
Vandetanib—EPHB6—tendon—psoriatic arthritis	0.00151	0.0189	CbGeAlD
Vandetanib—PDGFRB—skin of body—psoriatic arthritis	0.00147	0.0183	CbGeAlD
Vandetanib—YES1—tendon—psoriatic arthritis	0.00146	0.0182	CbGeAlD
Vandetanib—STK10—tendon—psoriatic arthritis	0.00145	0.0181	CbGeAlD
Vandetanib—ABL1—skin of body—psoriatic arthritis	0.00131	0.0163	CbGeAlD
Vandetanib—KDR—tendon—psoriatic arthritis	0.0013	0.0161	CbGeAlD
Vandetanib—MAP2K5—tendon—psoriatic arthritis	0.0013	0.0161	CbGeAlD
Vandetanib—PDGFRB—tendon—psoriatic arthritis	0.00112	0.014	CbGeAlD
Vandetanib—ABL1—tendon—psoriatic arthritis	0.000999	0.0124	CbGeAlD
Vandetanib—ABCC1—tendon—psoriatic arthritis	0.000761	0.00948	CbGeAlD
Vandetanib—VEGFA—Betamethasone—Methylprednisolone—psoriatic arthritis	0.000649	0.105	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Methylprednisolone—psoriatic arthritis	0.000649	0.105	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Dexamethasone—psoriatic arthritis	0.000639	0.104	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Betamethasone—psoriatic arthritis	0.000639	0.104	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Triamcinolone—psoriatic arthritis	0.000624	0.101	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Triamcinolone—psoriatic arthritis	0.000624	0.101	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Prednisone—psoriatic arthritis	0.000592	0.0961	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Prednisone—psoriatic arthritis	0.000592	0.0961	CbGdCrCtD
Vandetanib—VEGFA—Dexamethasone—Prednisolone—psoriatic arthritis	0.000578	0.0938	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Prednisolone—psoriatic arthritis	0.000578	0.0938	CbGdCrCtD
Vandetanib—Lethargy—Methotrexate—psoriatic arthritis	0.000482	0.00182	CcSEcCtD
Vandetanib—Arrhythmia—Prednisolone—psoriatic arthritis	0.000481	0.00182	CcSEcCtD
Vandetanib—Pancreatitis—Prednisone—psoriatic arthritis	0.000479	0.00181	CcSEcCtD
Vandetanib—Visual impairment—Methylprednisolone—psoriatic arthritis	0.000476	0.0018	CcSEcCtD
Vandetanib—Eye disorder—Methylprednisolone—psoriatic arthritis	0.000462	0.00174	CcSEcCtD
Vandetanib—Cardiac disorder—Methylprednisolone—psoriatic arthritis	0.000458	0.00173	CcSEcCtD
Vandetanib—Bradycardia—Dexamethasone—psoriatic arthritis	0.000457	0.00173	CcSEcCtD
Vandetanib—Bradycardia—Betamethasone—psoriatic arthritis	0.000457	0.00173	CcSEcCtD
Vandetanib—Neutropenia—Prednisone—psoriatic arthritis	0.000457	0.00173	CcSEcCtD
Vandetanib—Haemoglobin—Dexamethasone—psoriatic arthritis	0.000451	0.00171	CcSEcCtD
Vandetanib—Haemoglobin—Betamethasone—psoriatic arthritis	0.000451	0.00171	CcSEcCtD
Vandetanib—Haemorrhage—Betamethasone—psoriatic arthritis	0.000449	0.0017	CcSEcCtD
Vandetanib—Haemorrhage—Dexamethasone—psoriatic arthritis	0.000449	0.0017	CcSEcCtD
Vandetanib—Angiopathy—Methylprednisolone—psoriatic arthritis	0.000448	0.00169	CcSEcCtD
Vandetanib—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.000445	0.00168	CcSEcCtD
Vandetanib—Arrhythmia—Triamcinolone—psoriatic arthritis	0.000442	0.00167	CcSEcCtD
Vandetanib—Weight decreased—Prednisone—psoriatic arthritis	0.000442	0.00167	CcSEcCtD
Vandetanib—Vision blurred—Prednisolone—psoriatic arthritis	0.000442	0.00167	CcSEcCtD
Vandetanib—Arrhythmia—Methylprednisolone—psoriatic arthritis	0.000441	0.00167	CcSEcCtD
Vandetanib—Hyperglycaemia—Prednisone—psoriatic arthritis	0.000441	0.00167	CcSEcCtD
Vandetanib—Depression—Prednisone—psoriatic arthritis	0.000434	0.00164	CcSEcCtD
Vandetanib—Visual impairment—Dexamethasone—psoriatic arthritis	0.000433	0.00164	CcSEcCtD
Vandetanib—Visual impairment—Betamethasone—psoriatic arthritis	0.000433	0.00164	CcSEcCtD
Vandetanib—Mental disorder—Methylprednisolone—psoriatic arthritis	0.000433	0.00164	CcSEcCtD
Vandetanib—Malnutrition—Methylprednisolone—psoriatic arthritis	0.00043	0.00163	CcSEcCtD
Vandetanib—Dysgeusia—Triamcinolone—psoriatic arthritis	0.000422	0.0016	CcSEcCtD
Vandetanib—Eye disorder—Betamethasone—psoriatic arthritis	0.00042	0.00159	CcSEcCtD
Vandetanib—Eye disorder—Dexamethasone—psoriatic arthritis	0.00042	0.00159	CcSEcCtD
Vandetanib—Loss of consciousness—Prednisolone—psoriatic arthritis	0.000412	0.00156	CcSEcCtD
Vandetanib—Angiopathy—Dexamethasone—psoriatic arthritis	0.000408	0.00154	CcSEcCtD
Vandetanib—Angiopathy—Betamethasone—psoriatic arthritis	0.000408	0.00154	CcSEcCtD
Vandetanib—Convulsion—Prednisolone—psoriatic arthritis	0.000406	0.00153	CcSEcCtD
Vandetanib—Hypertension—Prednisolone—psoriatic arthritis	0.000405	0.00153	CcSEcCtD
Vandetanib—Arrhythmia—Betamethasone—psoriatic arthritis	0.000401	0.00152	CcSEcCtD
Vandetanib—Arrhythmia—Dexamethasone—psoriatic arthritis	0.000401	0.00152	CcSEcCtD
Vandetanib—Pancreatitis—Methotrexate—psoriatic arthritis	0.0004	0.00151	CcSEcCtD
Vandetanib—Bradycardia—Prednisone—psoriatic arthritis	0.000398	0.00151	CcSEcCtD
Vandetanib—Alopecia—Betamethasone—psoriatic arthritis	0.000397	0.0015	CcSEcCtD
Vandetanib—Alopecia—Dexamethasone—psoriatic arthritis	0.000397	0.0015	CcSEcCtD
Vandetanib—Haemoglobin—Prednisone—psoriatic arthritis	0.000393	0.00149	CcSEcCtD
Vandetanib—Haemorrhage—Prednisone—psoriatic arthritis	0.000391	0.00148	CcSEcCtD
Vandetanib—Oedema—Prednisolone—psoriatic arthritis	0.000382	0.00145	CcSEcCtD
Vandetanib—Neutropenia—Methotrexate—psoriatic arthritis	0.000382	0.00144	CcSEcCtD
Vandetanib—Dysuria—Methotrexate—psoriatic arthritis	0.000382	0.00144	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Methotrexate—psoriatic arthritis	0.00038	0.00143	CcSEcCtD
Vandetanib—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.000379	0.00143	CcSEcCtD
Vandetanib—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.000378	0.00143	CcSEcCtD
Vandetanib—Cough—Triamcinolone—psoriatic arthritis	0.000376	0.00142	CcSEcCtD
Vandetanib—Convulsion—Triamcinolone—psoriatic arthritis	0.000373	0.00141	CcSEcCtD
Vandetanib—Photosensitivity reaction—Methotrexate—psoriatic arthritis	0.000373	0.00141	CcSEcCtD
Vandetanib—Convulsion—Methylprednisolone—psoriatic arthritis	0.000373	0.00141	CcSEcCtD
Vandetanib—Hypertension—Triamcinolone—psoriatic arthritis	0.000372	0.00141	CcSEcCtD
Vandetanib—Hypertension—Methylprednisolone—psoriatic arthritis	0.000371	0.0014	CcSEcCtD
Vandetanib—Pneumonia—Methotrexate—psoriatic arthritis	0.000366	0.00138	CcSEcCtD
Vandetanib—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000366	0.00138	CcSEcCtD
Vandetanib—Eye disorder—Prednisone—psoriatic arthritis	0.000366	0.00138	CcSEcCtD
Vandetanib—Anxiety—Methylprednisolone—psoriatic arthritis	0.000365	0.00138	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—psoriatic arthritis	0.000364	0.00138	CcSEcCtD
Vandetanib—Infestation—Methotrexate—psoriatic arthritis	0.000364	0.00138	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000364	0.00137	CcSEcCtD
Vandetanib—Depression—Methotrexate—psoriatic arthritis	0.000363	0.00137	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.000361	0.00136	CcSEcCtD
Vandetanib—Dry mouth—Triamcinolone—psoriatic arthritis	0.000359	0.00136	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—psoriatic arthritis	0.000358	0.00135	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—psoriatic arthritis	0.000355	0.00134	CcSEcCtD
Vandetanib—Angiopathy—Prednisone—psoriatic arthritis	0.000355	0.00134	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—psoriatic arthritis	0.000354	0.00134	CcSEcCtD
Vandetanib—Oedema—Triamcinolone—psoriatic arthritis	0.000352	0.00133	CcSEcCtD
Vandetanib—Arrhythmia—Prednisone—psoriatic arthritis	0.000349	0.00132	CcSEcCtD
Vandetanib—Infection—Triamcinolone—psoriatic arthritis	0.000349	0.00132	CcSEcCtD
Vandetanib—Infection—Methylprednisolone—psoriatic arthritis	0.000349	0.00132	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—psoriatic arthritis	0.000347	0.00131	CcSEcCtD
Vandetanib—Insomnia—Prednisolone—psoriatic arthritis	0.000346	0.00131	CcSEcCtD
Vandetanib—Alopecia—Prednisone—psoriatic arthritis	0.000346	0.00131	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000344	0.0013	CcSEcCtD
Vandetanib—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000344	0.0013	CcSEcCtD
Vandetanib—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000344	0.0013	CcSEcCtD
Vandetanib—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000344	0.0013	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—psoriatic arthritis	0.000343	0.0013	CcSEcCtD
Vandetanib—Paraesthesia—Prednisolone—psoriatic arthritis	0.000343	0.0013	CcSEcCtD
Vandetanib—Mental disorder—Prednisone—psoriatic arthritis	0.000343	0.0013	CcSEcCtD
Vandetanib—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000341	0.00129	CcSEcCtD
Vandetanib—Malnutrition—Prednisone—psoriatic arthritis	0.000341	0.00129	CcSEcCtD
Vandetanib—Convulsion—Dexamethasone—psoriatic arthritis	0.000339	0.00128	CcSEcCtD
Vandetanib—Convulsion—Betamethasone—psoriatic arthritis	0.000339	0.00128	CcSEcCtD
Vandetanib—Hypertension—Dexamethasone—psoriatic arthritis	0.000338	0.00128	CcSEcCtD
Vandetanib—Hypertension—Betamethasone—psoriatic arthritis	0.000338	0.00128	CcSEcCtD
Vandetanib—Anxiety—Betamethasone—psoriatic arthritis	0.000332	0.00125	CcSEcCtD
Vandetanib—Anxiety—Dexamethasone—psoriatic arthritis	0.000332	0.00125	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—psoriatic arthritis	0.000329	0.00124	CcSEcCtD
Vandetanib—Pain—Prednisolone—psoriatic arthritis	0.000327	0.00124	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—psoriatic arthritis	0.000327	0.00124	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000323	0.00122	CcSEcCtD
Vandetanib—Vision blurred—Prednisone—psoriatic arthritis	0.000321	0.00121	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—psoriatic arthritis	0.00032	0.00121	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00032	0.00121	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.00032	0.00121	CcSEcCtD
Vandetanib—Oedema—Betamethasone—psoriatic arthritis	0.000319	0.00121	CcSEcCtD
Vandetanib—Oedema—Dexamethasone—psoriatic arthritis	0.000319	0.00121	CcSEcCtD
Vandetanib—Insomnia—Triamcinolone—psoriatic arthritis	0.000318	0.0012	CcSEcCtD
Vandetanib—Insomnia—Methylprednisolone—psoriatic arthritis	0.000317	0.0012	CcSEcCtD
Vandetanib—Infection—Betamethasone—psoriatic arthritis	0.000317	0.0012	CcSEcCtD
Vandetanib—Infection—Dexamethasone—psoriatic arthritis	0.000317	0.0012	CcSEcCtD
Vandetanib—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000316	0.00119	CcSEcCtD
Vandetanib—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000315	0.00119	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—psoriatic arthritis	0.000315	0.00119	CcSEcCtD
Vandetanib—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000314	0.00119	CcSEcCtD
Vandetanib—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000313	0.00118	CcSEcCtD
Vandetanib—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000313	0.00118	CcSEcCtD
Vandetanib—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000312	0.00118	CcSEcCtD
Vandetanib—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000312	0.00118	CcSEcCtD
Vandetanib—Dyspepsia—Triamcinolone—psoriatic arthritis	0.00031	0.00117	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—psoriatic arthritis	0.000309	0.00117	CcSEcCtD
Vandetanib—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000309	0.00117	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—psoriatic arthritis	0.000306	0.00115	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000303	0.00115	CcSEcCtD
Vandetanib—Fatigue—Triamcinolone—psoriatic arthritis	0.000303	0.00115	CcSEcCtD
Vandetanib—Fatigue—Methylprednisolone—psoriatic arthritis	0.000303	0.00114	CcSEcCtD
Vandetanib—Pain—Triamcinolone—psoriatic arthritis	0.000301	0.00114	CcSEcCtD
Vandetanib—Loss of consciousness—Prednisone—psoriatic arthritis	0.000299	0.00113	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—psoriatic arthritis	0.000297	0.00112	CcSEcCtD
Vandetanib—Convulsion—Prednisone—psoriatic arthritis	0.000295	0.00112	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000295	0.00111	CcSEcCtD
Vandetanib—Hypertension—Prednisone—psoriatic arthritis	0.000294	0.00111	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.000291	0.0011	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.000291	0.0011	CcSEcCtD
Vandetanib—Arthralgia—Prednisone—psoriatic arthritis	0.00029	0.0011	CcSEcCtD
Vandetanib—Anxiety—Prednisone—psoriatic arthritis	0.000289	0.00109	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—psoriatic arthritis	0.000289	0.00109	CcSEcCtD
Vandetanib—Insomnia—Betamethasone—psoriatic arthritis	0.000289	0.00109	CcSEcCtD
Vandetanib—Insomnia—Dexamethasone—psoriatic arthritis	0.000289	0.00109	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000288	0.00109	CcSEcCtD
Vandetanib—ERBB3—Immune System—MEFV—psoriatic arthritis	0.000287	0.00144	CbGpPWpGaD
Vandetanib—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000287	0.00108	CcSEcCtD
Vandetanib—RIPK2—Innate Immune System—HLA-C—psoriatic arthritis	0.000287	0.00144	CbGpPWpGaD
Vandetanib—Paraesthesia—Betamethasone—psoriatic arthritis	0.000287	0.00108	CcSEcCtD
Vandetanib—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000287	0.00108	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—psoriatic arthritis	0.000286	0.00108	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—psoriatic arthritis	0.000285	0.00108	CcSEcCtD
Vandetanib—IRAK4—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000283	0.00142	CbGpPWpGaD
Vandetanib—Dyspepsia—Betamethasone—psoriatic arthritis	0.000281	0.00106	CcSEcCtD
Vandetanib—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000281	0.00106	CcSEcCtD
Vandetanib—SRC—CXCR4-mediated signaling events—HLA-DRB1—psoriatic arthritis	0.000281	0.00141	CbGpPWpGaD
Vandetanib—Dysgeusia—Methotrexate—psoriatic arthritis	0.000279	0.00105	CcSEcCtD
Vandetanib—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000278	0.00105	CcSEcCtD
Vandetanib—Oedema—Prednisone—psoriatic arthritis	0.000278	0.00105	CcSEcCtD
Vandetanib—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000277	0.00105	CcSEcCtD
Vandetanib—Decreased appetite—Betamethasone—psoriatic arthritis	0.000277	0.00105	CcSEcCtD
Vandetanib—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000277	0.00105	CcSEcCtD
Vandetanib—Infection—Prednisone—psoriatic arthritis	0.000276	0.00104	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000276	0.00104	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000276	0.00104	CcSEcCtD
Vandetanib—RIPK2—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000275	0.00138	CbGpPWpGaD
Vandetanib—Fatigue—Betamethasone—psoriatic arthritis	0.000275	0.00104	CcSEcCtD
Vandetanib—Fatigue—Dexamethasone—psoriatic arthritis	0.000275	0.00104	CcSEcCtD
Vandetanib—EGFR—Innate Immune System—MEFV—psoriatic arthritis	0.000275	0.00138	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—HLA-C—psoriatic arthritis	0.000275	0.00138	CbGpPWpGaD
Vandetanib—Pain—Dexamethasone—psoriatic arthritis	0.000273	0.00103	CcSEcCtD
Vandetanib—Pain—Betamethasone—psoriatic arthritis	0.000273	0.00103	CcSEcCtD
Vandetanib—FYN—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriatic arthritis	0.000273	0.00137	CbGpPWpGaD
Vandetanib—Nervous system disorder—Prednisone—psoriatic arthritis	0.000273	0.00103	CcSEcCtD
Vandetanib—MKNK1—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000271	0.00136	CbGpPWpGaD
Vandetanib—Skin disorder—Prednisone—psoriatic arthritis	0.00027	0.00102	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—psoriatic arthritis	0.000268	0.00101	CcSEcCtD
Vandetanib—VEGFA—Allograft Rejection—TNF—psoriatic arthritis	0.000267	0.00134	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—MEFV—psoriatic arthritis	0.000265	0.00133	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000265	0.00133	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—REL—psoriatic arthritis	0.000264	0.00132	CbGpPWpGaD
Vandetanib—ABL1—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—psoriatic arthritis	0.000263	0.00132	CbGpPWpGaD
Vandetanib—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000261	0.000986	CcSEcCtD
Vandetanib—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000261	0.000986	CcSEcCtD
Vandetanib—PDGFRB—DAP12 interactions—HLA-B—psoriatic arthritis	0.000257	0.00129	CbGpPWpGaD
Vandetanib—RIPK2—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000256	0.00129	CbGpPWpGaD
Vandetanib—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000253	0.000957	CcSEcCtD
Vandetanib—Dizziness—Prednisolone—psoriatic arthritis	0.000253	0.000956	CcSEcCtD
Vandetanib—ERBB3—Innate Immune System—HLA-C—psoriatic arthritis	0.000253	0.00127	CbGpPWpGaD
Vandetanib—YES1—Immune System—MEFV—psoriatic arthritis	0.000252	0.00127	CbGpPWpGaD
Vandetanib—Asthenia—Triamcinolone—psoriatic arthritis	0.000252	0.000954	CcSEcCtD
Vandetanib—Abdominal pain—Betamethasone—psoriatic arthritis	0.000252	0.000953	CcSEcCtD
Vandetanib—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000252	0.000953	CcSEcCtD
Vandetanib—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000252	0.000953	CcSEcCtD
Vandetanib—Body temperature increased—Betamethasone—psoriatic arthritis	0.000252	0.000953	CcSEcCtD
Vandetanib—Asthenia—Methylprednisolone—psoriatic arthritis	0.000252	0.000952	CcSEcCtD
Vandetanib—EGFR—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000252	0.00126	CbGpPWpGaD
Vandetanib—EGFR—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000252	0.00126	CbGpPWpGaD
Vandetanib—Insomnia—Prednisone—psoriatic arthritis	0.000251	0.00095	CcSEcCtD
Vandetanib—Paraesthesia—Prednisone—psoriatic arthritis	0.00025	0.000943	CcSEcCtD
Vandetanib—Pruritus—Triamcinolone—psoriatic arthritis	0.000249	0.00094	CcSEcCtD
Vandetanib—Cough—Methotrexate—psoriatic arthritis	0.000248	0.000939	CcSEcCtD
Vandetanib—Pruritus—Methylprednisolone—psoriatic arthritis	0.000248	0.000938	CcSEcCtD
Vandetanib—FYN—DAP12 interactions—HLA-B—psoriatic arthritis	0.000248	0.00125	CbGpPWpGaD
Vandetanib—Convulsion—Methotrexate—psoriatic arthritis	0.000247	0.000932	CcSEcCtD
Vandetanib—Dyspepsia—Prednisone—psoriatic arthritis	0.000245	0.000925	CcSEcCtD
Vandetanib—ERBB3—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000243	0.00122	CbGpPWpGaD
Vandetanib—Arthralgia—Methotrexate—psoriatic arthritis	0.000242	0.000916	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—psoriatic arthritis	0.000242	0.000916	CcSEcCtD
Vandetanib—LCK—Cytokine Signaling in Immune system—HLA-C—psoriatic arthritis	0.000242	0.00121	CbGpPWpGaD
Vandetanib—Decreased appetite—Prednisone—psoriatic arthritis	0.000242	0.000913	CcSEcCtD
Vandetanib—Rash—Prednisolone—psoriatic arthritis	0.000241	0.000911	CcSEcCtD
Vandetanib—Dermatitis—Prednisolone—psoriatic arthritis	0.000241	0.000911	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000241	0.000909	CcSEcCtD
Vandetanib—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00024	0.000908	CcSEcCtD
Vandetanib—ALB—Folate Metabolism—CRP—psoriatic arthritis	0.00024	0.00121	CbGpPWpGaD
Vandetanib—Fatigue—Prednisone—psoriatic arthritis	0.00024	0.000906	CcSEcCtD
Vandetanib—Headache—Prednisolone—psoriatic arthritis	0.00024	0.000906	CcSEcCtD
Vandetanib—EGFR—Spinal Cord Injury—NOS2—psoriatic arthritis	0.000239	0.0012	CbGpPWpGaD
Vandetanib—Constipation—Prednisone—psoriatic arthritis	0.000238	0.000898	CcSEcCtD
Vandetanib—SRC—Innate Immune System—MEFV—psoriatic arthritis	0.000234	0.00118	CbGpPWpGaD
Vandetanib—IRAK4—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000234	0.00118	CbGpPWpGaD
Vandetanib—YES1—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000234	0.00118	CbGpPWpGaD
Vandetanib—IRAK4—Innate Immune System—NOD2—psoriatic arthritis	0.000233	0.00117	CbGpPWpGaD
Vandetanib—Dizziness—Triamcinolone—psoriatic arthritis	0.000233	0.000879	CcSEcCtD
Vandetanib—Dizziness—Methylprednisolone—psoriatic arthritis	0.000232	0.000877	CcSEcCtD
Vandetanib—YES1—Adaptive Immune System—REL—psoriatic arthritis	0.000231	0.00116	CbGpPWpGaD
Vandetanib—Infection—Methotrexate—psoriatic arthritis	0.000231	0.000872	CcSEcCtD
Vandetanib—Asthenia—Betamethasone—psoriatic arthritis	0.000229	0.000865	CcSEcCtD
Vandetanib—Asthenia—Dexamethasone—psoriatic arthritis	0.000229	0.000865	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000228	0.000861	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000227	0.00086	CcSEcCtD
Vandetanib—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000227	0.000859	CcSEcCtD
Vandetanib—Nausea—Prednisolone—psoriatic arthritis	0.000227	0.000859	CcSEcCtD
Vandetanib—Pruritus—Dexamethasone—psoriatic arthritis	0.000226	0.000853	CcSEcCtD
Vandetanib—Pruritus—Betamethasone—psoriatic arthritis	0.000226	0.000853	CcSEcCtD
Vandetanib—TEK—Hemostasis—NOS2—psoriatic arthritis	0.000226	0.00113	CbGpPWpGaD
Vandetanib—Skin disorder—Methotrexate—psoriatic arthritis	0.000226	0.000853	CcSEcCtD
Vandetanib—Vomiting—Triamcinolone—psoriatic arthritis	0.000224	0.000845	CcSEcCtD
Vandetanib—Vomiting—Methylprednisolone—psoriatic arthritis	0.000223	0.000843	CcSEcCtD
Vandetanib—YES1—Innate Immune System—HLA-C—psoriatic arthritis	0.000222	0.00111	CbGpPWpGaD
Vandetanib—Rash—Triamcinolone—psoriatic arthritis	0.000222	0.000838	CcSEcCtD
Vandetanib—Dermatitis—Triamcinolone—psoriatic arthritis	0.000222	0.000837	CcSEcCtD
Vandetanib—Rash—Methylprednisolone—psoriatic arthritis	0.000221	0.000836	CcSEcCtD
Vandetanib—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000221	0.000836	CcSEcCtD
Vandetanib—Headache—Triamcinolone—psoriatic arthritis	0.00022	0.000833	CcSEcCtD
Vandetanib—Headache—Methylprednisolone—psoriatic arthritis	0.00022	0.000831	CcSEcCtD
Vandetanib—Abdominal pain—Prednisone—psoriatic arthritis	0.00022	0.00083	CcSEcCtD
Vandetanib—Body temperature increased—Prednisone—psoriatic arthritis	0.00022	0.00083	CcSEcCtD
Vandetanib—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000218	0.000825	CcSEcCtD
Vandetanib—Diarrhoea—Betamethasone—psoriatic arthritis	0.000218	0.000825	CcSEcCtD
Vandetanib—LYN—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000217	0.00109	CbGpPWpGaD
Vandetanib—FMO3—SIDS Susceptibility Pathways—TNF—psoriatic arthritis	0.000217	0.00109	CbGpPWpGaD
Vandetanib—SRC—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000215	0.00108	CbGpPWpGaD
Vandetanib—SRC—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.000215	0.00108	CbGpPWpGaD
Vandetanib—EGFR—DAP12 interactions—HLA-B—psoriatic arthritis	0.000214	0.00108	CbGpPWpGaD
Vandetanib—FYN—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000214	0.00107	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000213	0.00107	CbGpPWpGaD
Vandetanib—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000212	0.0008	CcSEcCtD
Vandetanib—Dizziness—Betamethasone—psoriatic arthritis	0.000211	0.000798	CcSEcCtD
Vandetanib—Dizziness—Dexamethasone—psoriatic arthritis	0.000211	0.000798	CcSEcCtD
Vandetanib—RIPK2—Innate Immune System—NOD2—psoriatic arthritis	0.000211	0.00106	CbGpPWpGaD
Vandetanib—Insomnia—Methotrexate—psoriatic arthritis	0.00021	0.000794	CcSEcCtD
Vandetanib—Nausea—Triamcinolone—psoriatic arthritis	0.000209	0.00079	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—psoriatic arthritis	0.000209	0.000788	CcSEcCtD
Vandetanib—Nausea—Methylprednisolone—psoriatic arthritis	0.000208	0.000788	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—psoriatic arthritis	0.000207	0.000783	CcSEcCtD
Vandetanib—LCK—DAP12 interactions—HLA-B—psoriatic arthritis	0.000206	0.00104	CbGpPWpGaD
Vandetanib—Dyspepsia—Methotrexate—psoriatic arthritis	0.000204	0.000773	CcSEcCtD
Vandetanib—Vomiting—Betamethasone—psoriatic arthritis	0.000203	0.000767	CcSEcCtD
Vandetanib—Vomiting—Dexamethasone—psoriatic arthritis	0.000203	0.000767	CcSEcCtD
Vandetanib—FGR—Innate Immune System—NOD2—psoriatic arthritis	0.000202	0.00102	CbGpPWpGaD
Vandetanib—Decreased appetite—Methotrexate—psoriatic arthritis	0.000202	0.000763	CcSEcCtD
Vandetanib—Rash—Dexamethasone—psoriatic arthritis	0.000201	0.000761	CcSEcCtD
Vandetanib—Rash—Betamethasone—psoriatic arthritis	0.000201	0.000761	CcSEcCtD
Vandetanib—Dermatitis—Betamethasone—psoriatic arthritis	0.000201	0.00076	CcSEcCtD
Vandetanib—Dermatitis—Dexamethasone—psoriatic arthritis	0.000201	0.00076	CcSEcCtD
Vandetanib—IRAK4—Immune System—REL—psoriatic arthritis	0.000201	0.00101	CbGpPWpGaD
Vandetanib—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000201	0.000758	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—psoriatic arthritis	0.0002	0.000757	CcSEcCtD
Vandetanib—Headache—Betamethasone—psoriatic arthritis	0.0002	0.000756	CcSEcCtD
Vandetanib—Headache—Dexamethasone—psoriatic arthritis	0.0002	0.000756	CcSEcCtD
Vandetanib—Asthenia—Prednisone—psoriatic arthritis	0.000199	0.000754	CcSEcCtD
Vandetanib—Pain—Methotrexate—psoriatic arthritis	0.000199	0.000751	CcSEcCtD
Vandetanib—YES1—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000198	0.000995	CbGpPWpGaD
Vandetanib—Pruritus—Prednisone—psoriatic arthritis	0.000197	0.000743	CcSEcCtD
Vandetanib—PDGFRB—Immune System—MEFV—psoriatic arthritis	0.000192	0.000966	CbGpPWpGaD
Vandetanib—ALB—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000191	0.000958	CbGpPWpGaD
Vandetanib—Diarrhoea—Prednisone—psoriatic arthritis	0.00019	0.000719	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00019	0.000718	CcSEcCtD
Vandetanib—Nausea—Dexamethasone—psoriatic arthritis	0.00019	0.000716	CcSEcCtD
Vandetanib—Nausea—Betamethasone—psoriatic arthritis	0.00019	0.000716	CcSEcCtD
Vandetanib—LYN—Immune System—MEFV—psoriatic arthritis	0.000188	0.000945	CbGpPWpGaD
Vandetanib—IRAK4—Innate Immune System—HLA-B—psoriatic arthritis	0.000187	0.000942	CbGpPWpGaD
Vandetanib—ABL1—Immune System—MEFV—psoriatic arthritis	0.000187	0.000941	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—NOD2—psoriatic arthritis	0.000186	0.000934	CbGpPWpGaD
Vandetanib—FYN—Immune System—MEFV—psoriatic arthritis	0.000185	0.000931	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—HLA-C—psoriatic arthritis	0.000185	0.000927	CbGpPWpGaD
Vandetanib—Dizziness—Prednisone—psoriatic arthritis	0.000184	0.000695	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—psoriatic arthritis	0.000184	0.000694	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—psoriatic arthritis	0.000184	0.000694	CcSEcCtD
Vandetanib—RIPK2—Immune System—REL—psoriatic arthritis	0.000181	0.000911	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—NOD2—psoriatic arthritis	0.000178	0.000893	CbGpPWpGaD
Vandetanib—Vomiting—Prednisone—psoriatic arthritis	0.000177	0.000668	CcSEcCtD
Vandetanib—PDGFRB—Adaptive Immune System—REL—psoriatic arthritis	0.000176	0.000886	CbGpPWpGaD
Vandetanib—Rash—Prednisone—psoriatic arthritis	0.000175	0.000662	CcSEcCtD
Vandetanib—Dermatitis—Prednisone—psoriatic arthritis	0.000175	0.000662	CcSEcCtD
Vandetanib—BLK—Immune System—REL—psoriatic arthritis	0.000174	0.000877	CbGpPWpGaD
Vandetanib—LYN—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000174	0.000876	CbGpPWpGaD
Vandetanib—Headache—Prednisone—psoriatic arthritis	0.000174	0.000658	CcSEcCtD
Vandetanib—FGR—Immune System—REL—psoriatic arthritis	0.000174	0.000874	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—REL—psoriatic arthritis	0.000173	0.000867	CbGpPWpGaD
Vandetanib—FYN—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000172	0.000863	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—REL—psoriatic arthritis	0.00017	0.000854	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—HLA-B—psoriatic arthritis	0.000169	0.000852	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—HLA-C—psoriatic arthritis	0.000169	0.000849	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—HLA-C—psoriatic arthritis	0.000167	0.000839	CbGpPWpGaD
Vandetanib—Asthenia—Methotrexate—psoriatic arthritis	0.000167	0.00063	CcSEcCtD
Vandetanib—MAP2K5—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000166	0.000836	CbGpPWpGaD
Vandetanib—IRAK4—Innate Immune System—CRP—psoriatic arthritis	0.000166	0.000832	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—HLA-C—psoriatic arthritis	0.000165	0.000831	CbGpPWpGaD
Vandetanib—Nausea—Prednisone—psoriatic arthritis	0.000165	0.000624	CcSEcCtD
Vandetanib—ABL1—Innate Immune System—HLA-C—psoriatic arthritis	0.000165	0.000827	CbGpPWpGaD
Vandetanib—Pruritus—Methotrexate—psoriatic arthritis	0.000164	0.000621	CcSEcCtD
Vandetanib—YES1—Innate Immune System—NOD2—psoriatic arthritis	0.000163	0.000819	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—HLA-C—psoriatic arthritis	0.000163	0.000818	CbGpPWpGaD
Vandetanib—RIPK2—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000163	0.000818	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—HLA-B—psoriatic arthritis	0.000162	0.000816	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000162	0.000815	CbGpPWpGaD
Vandetanib—BLK—Immune System—HLA-C—psoriatic arthritis	0.000161	0.000807	CbGpPWpGaD
Vandetanib—FGR—Immune System—HLA-C—psoriatic arthritis	0.00016	0.000804	CbGpPWpGaD
Vandetanib—EGFR—Immune System—MEFV—psoriatic arthritis	0.00016	0.000804	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—REL—psoriatic arthritis	0.00016	0.000803	CbGpPWpGaD
Vandetanib—Diarrhoea—Methotrexate—psoriatic arthritis	0.000159	0.000601	CcSEcCtD
Vandetanib—LYN—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000159	0.000798	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000157	0.000787	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000156	0.000786	CbGpPWpGaD
Vandetanib—VEGFA—SIDS Susceptibility Pathways—TNF—psoriatic arthritis	0.000155	0.000777	CbGpPWpGaD
Vandetanib—LCK—Immune System—MEFV—psoriatic arthritis	0.000154	0.000775	CbGpPWpGaD
Vandetanib—Dizziness—Methotrexate—psoriatic arthritis	0.000154	0.000581	CcSEcCtD
Vandetanib—RIPK2—Innate Immune System—CRP—psoriatic arthritis	0.00015	0.000753	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—HLA-B—psoriatic arthritis	0.000149	0.000751	CbGpPWpGaD
Vandetanib—Vomiting—Methotrexate—psoriatic arthritis	0.000148	0.000558	CcSEcCtD
Vandetanib—LYN—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000148	0.000742	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HLA-C—psoriatic arthritis	0.000147	0.000739	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—REL—psoriatic arthritis	0.000147	0.000737	CbGpPWpGaD
Vandetanib—Rash—Methotrexate—psoriatic arthritis	0.000146	0.000554	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—psoriatic arthritis	0.000146	0.000553	CcSEcCtD
Vandetanib—Headache—Methotrexate—psoriatic arthritis	0.000146	0.00055	CcSEcCtD
Vandetanib—FGR—Hemostasis—NOS2—psoriatic arthritis	0.000145	0.000731	CbGpPWpGaD
Vandetanib—FYN—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000145	0.00073	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—CRP—psoriatic arthritis	0.000144	0.000722	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000143	0.000721	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—HLA-B—psoriatic arthritis	0.000143	0.000718	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—REL—psoriatic arthritis	0.000141	0.000711	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—HLA-C—psoriatic arthritis	0.000141	0.000707	CbGpPWpGaD
Vandetanib—YES1—Immune System—REL—psoriatic arthritis	0.00014	0.000705	CbGpPWpGaD
Vandetanib—Nausea—Methotrexate—psoriatic arthritis	0.000138	0.000521	CcSEcCtD
Vandetanib—RIPK2—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000138	0.000692	CbGpPWpGaD
Vandetanib—SRC—Immune System—MEFV—psoriatic arthritis	0.000137	0.000686	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—NOD2—psoriatic arthritis	0.000136	0.000682	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HLA-C—psoriatic arthritis	0.000136	0.000681	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000135	0.000679	CbGpPWpGaD
Vandetanib—ALB—Vitamin B12 Metabolism—TNF—psoriatic arthritis	0.000134	0.000671	CbGpPWpGaD
Vandetanib—BLK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000133	0.000666	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—CRP—psoriatic arthritis	0.000132	0.000664	CbGpPWpGaD
Vandetanib—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000132	0.000661	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—HLA-B—psoriatic arthritis	0.000131	0.000659	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-C—psoriatic arthritis	0.00013	0.000654	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-C—psoriatic arthritis	0.000129	0.000649	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—HLA-B—psoriatic arthritis	0.000126	0.000633	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—REL—psoriatic arthritis	0.000125	0.000629	CbGpPWpGaD
Vandetanib—EPHA5—Developmental Biology—TNF—psoriatic arthritis	0.000125	0.000628	CbGpPWpGaD
Vandetanib—ABL2—Developmental Biology—TNF—psoriatic arthritis	0.000125	0.000628	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—NOD2—psoriatic arthritis	0.000124	0.000624	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—NOD2—psoriatic arthritis	0.000123	0.000617	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—NOD2—psoriatic arthritis	0.000122	0.000611	CbGpPWpGaD
Vandetanib—VEGFA—Hemostasis—NOS2—psoriatic arthritis	0.000122	0.000611	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000121	0.00061	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—NOD2—psoriatic arthritis	0.000121	0.000608	CbGpPWpGaD
Vandetanib—LCK—Cytokine Signaling in Immune system—HLA-DRB1—psoriatic arthritis	0.000121	0.000608	CbGpPWpGaD
Vandetanib—EPHA8—Developmental Biology—TNF—psoriatic arthritis	0.000121	0.000605	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HLA-C—psoriatic arthritis	0.00012	0.000603	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—NOD2—psoriatic arthritis	0.00012	0.000602	CbGpPWpGaD
Vandetanib—EGFR—Spinal Cord Injury—TNF—psoriatic arthritis	0.000118	0.000595	CbGpPWpGaD
Vandetanib—BLK—Immune System—NOD2—psoriatic arthritis	0.000118	0.000593	CbGpPWpGaD
Vandetanib—FGR—Immune System—NOD2—psoriatic arthritis	0.000118	0.000591	CbGpPWpGaD
Vandetanib—YES1—Hemostasis—NOS2—psoriatic arthritis	0.000117	0.00059	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—CRP—psoriatic arthritis	0.000116	0.000582	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-C—psoriatic arthritis	0.000115	0.000579	CbGpPWpGaD
Vandetanib—EPHB6—Developmental Biology—TNF—psoriatic arthritis	0.000112	0.000563	CbGpPWpGaD
Vandetanib—MKNK1—Disease—NOS2—psoriatic arthritis	0.000109	0.000549	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—HLA-B—psoriatic arthritis	0.000109	0.000548	CbGpPWpGaD
Vandetanib—ALB—Folate Metabolism—TNF—psoriatic arthritis	0.000109	0.000546	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—NOD2—psoriatic arthritis	0.000108	0.000544	CbGpPWpGaD
Vandetanib—PDGFRB—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000107	0.000539	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—REL—psoriatic arthritis	0.000107	0.000537	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	0.000107	0.000536	CbGpPWpGaD
Vandetanib—EPHA6—Developmental Biology—TNF—psoriatic arthritis	0.000105	0.000529	CbGpPWpGaD
Vandetanib—LYN—Immune System—REL—psoriatic arthritis	0.000105	0.000526	CbGpPWpGaD
Vandetanib—ABL1—Immune System—REL—psoriatic arthritis	0.000104	0.000523	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—NOD2—psoriatic arthritis	0.000103	0.00052	CbGpPWpGaD
Vandetanib—FYN—Immune System—REL—psoriatic arthritis	0.000103	0.000518	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—HLA-B—psoriatic arthritis	9.99e-05	0.000502	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—NOD2—psoriatic arthritis	9.97e-05	0.000501	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—HLA-B—psoriatic arthritis	9.87e-05	0.000496	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-C—psoriatic arthritis	9.84e-05	0.000494	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—HLA-B—psoriatic arthritis	9.78e-05	0.000491	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—HLA-B—psoriatic arthritis	9.73e-05	0.000489	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—CRP—psoriatic arthritis	9.65e-05	0.000485	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-C—psoriatic arthritis	9.63e-05	0.000484	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—HLA-B—psoriatic arthritis	9.63e-05	0.000484	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HLA-B—psoriatic arthritis	9.59e-05	0.000482	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-C—psoriatic arthritis	9.59e-05	0.000482	CbGpPWpGaD
Vandetanib—YES1—Immune System—NOD2—psoriatic arthritis	9.5e-05	0.000477	CbGpPWpGaD
Vandetanib—BLK—Immune System—HLA-B—psoriatic arthritis	9.5e-05	0.000477	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-C—psoriatic arthritis	9.48e-05	0.000476	CbGpPWpGaD
Vandetanib—FGR—Immune System—HLA-B—psoriatic arthritis	9.46e-05	0.000475	CbGpPWpGaD
Vandetanib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	9.43e-05	0.000474	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HLA-B—psoriatic arthritis	9.39e-05	0.000472	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HLA-B—psoriatic arthritis	9.25e-05	0.000465	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—HLA-DRB1—psoriatic arthritis	9.24e-05	0.000464	CbGpPWpGaD
Vandetanib—EGFR—MAPK Signaling Pathway—TNF—psoriatic arthritis	8.93e-05	0.000449	CbGpPWpGaD
Vandetanib—EGFR—Immune System—REL—psoriatic arthritis	8.9e-05	0.000447	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—CRP—psoriatic arthritis	8.83e-05	0.000444	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—NOD2—psoriatic arthritis	8.83e-05	0.000443	CbGpPWpGaD
Vandetanib—LYN—Hemostasis—NOS2—psoriatic arthritis	8.76e-05	0.00044	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—CRP—psoriatic arthritis	8.73e-05	0.000438	CbGpPWpGaD
Vandetanib—ABL1—Hemostasis—NOS2—psoriatic arthritis	8.72e-05	0.000438	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HLA-B—psoriatic arthritis	8.7e-05	0.000437	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—CRP—psoriatic arthritis	8.64e-05	0.000434	CbGpPWpGaD
Vandetanib—ALB—Selenium Micronutrient Network—TNF—psoriatic arthritis	8.63e-05	0.000434	CbGpPWpGaD
Vandetanib—FYN—Hemostasis—NOS2—psoriatic arthritis	8.62e-05	0.000433	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—CRP—psoriatic arthritis	8.6e-05	0.000432	CbGpPWpGaD
Vandetanib—LCK—Immune System—REL—psoriatic arthritis	8.58e-05	0.000431	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—CRP—psoriatic arthritis	8.51e-05	0.000428	CbGpPWpGaD
Vandetanib—BLK—Immune System—CRP—psoriatic arthritis	8.39e-05	0.000422	CbGpPWpGaD
Vandetanib—FGR—Immune System—CRP—psoriatic arthritis	8.37e-05	0.00042	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—HLA-DRB1—psoriatic arthritis	8.36e-05	0.00042	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—HLA-B—psoriatic arthritis	8.32e-05	0.000418	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-C—psoriatic arthritis	8.19e-05	0.000412	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	8.12e-05	0.000408	CbGpPWpGaD
Vandetanib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	8.06e-05	0.000405	CbGpPWpGaD
Vandetanib—BLK—Immune System—HLA-DRB1—psoriatic arthritis	8.04e-05	0.000404	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HLA-B—psoriatic arthritis	8.02e-05	0.000403	CbGpPWpGaD
Vandetanib—FGR—Immune System—HLA-DRB1—psoriatic arthritis	8.01e-05	0.000403	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HLA-B—psoriatic arthritis	7.99e-05	0.000401	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.95e-05	0.000399	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-C—psoriatic arthritis	7.9e-05	0.000397	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	7.83e-05	0.000393	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-B—psoriatic arthritis	7.7e-05	0.000387	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—CRP—psoriatic arthritis	7.69e-05	0.000386	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-B—psoriatic arthritis	7.64e-05	0.000384	CbGpPWpGaD
Vandetanib—SRC—Immune System—REL—psoriatic arthritis	7.59e-05	0.000382	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—HLA-DRB1—psoriatic arthritis	7.37e-05	0.00037	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—CRP—psoriatic arthritis	7.35e-05	0.000369	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—NOD2—psoriatic arthritis	7.24e-05	0.000364	CbGpPWpGaD
Vandetanib—LCK—Hemostasis—NOS2—psoriatic arthritis	7.18e-05	0.000361	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HLA-B—psoriatic arthritis	7.1e-05	0.000357	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—CRP—psoriatic arthritis	7.09e-05	0.000356	CbGpPWpGaD
Vandetanib—LYN—Immune System—NOD2—psoriatic arthritis	7.08e-05	0.000356	CbGpPWpGaD
Vandetanib—ABL1—Immune System—NOD2—psoriatic arthritis	7.05e-05	0.000354	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-C—psoriatic arthritis	6.99e-05	0.000351	CbGpPWpGaD
Vandetanib—FYN—Immune System—NOD2—psoriatic arthritis	6.97e-05	0.00035	CbGpPWpGaD
Vandetanib—SRC—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	6.88e-05	0.000345	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—TNF—psoriatic arthritis	6.84e-05	0.000344	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-B—psoriatic arthritis	6.81e-05	0.000342	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.76e-05	0.00034	CbGpPWpGaD
Vandetanib—YES1—Immune System—CRP—psoriatic arthritis	6.75e-05	0.000339	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	6.52e-05	0.000327	CbGpPWpGaD
Vandetanib—ERBB3—Disease—NOS2—psoriatic arthritis	6.48e-05	0.000325	CbGpPWpGaD
Vandetanib—YES1—Immune System—HLA-DRB1—psoriatic arthritis	6.47e-05	0.000325	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—NOS2—psoriatic arthritis	6.35e-05	0.000319	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—CRP—psoriatic arthritis	6.27e-05	0.000315	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—TNF—psoriatic arthritis	6.15e-05	0.000309	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NOD2—psoriatic arthritis	6.02e-05	0.000303	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—TNF—psoriatic arthritis	5.94e-05	0.000299	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-B—psoriatic arthritis	5.82e-05	0.000292	CbGpPWpGaD
Vandetanib—LCK—Immune System—NOD2—psoriatic arthritis	5.81e-05	0.000292	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HLA-DRB1—psoriatic arthritis	5.77e-05	0.00029	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-B—psoriatic arthritis	5.7e-05	0.000286	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-B—psoriatic arthritis	5.67e-05	0.000285	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-B—psoriatic arthritis	5.61e-05	0.000282	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CRP—psoriatic arthritis	5.14e-05	0.000258	CbGpPWpGaD
Vandetanib—SRC—Immune System—NOD2—psoriatic arthritis	5.14e-05	0.000258	CbGpPWpGaD
Vandetanib—LYN—Immune System—CRP—psoriatic arthritis	5.03e-05	0.000253	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CRP—psoriatic arthritis	5.01e-05	0.000252	CbGpPWpGaD
Vandetanib—FYN—Immune System—CRP—psoriatic arthritis	4.96e-05	0.000249	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HLA-DRB1—psoriatic arthritis	4.92e-05	0.000247	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-B—psoriatic arthritis	4.84e-05	0.000243	CbGpPWpGaD
Vandetanib—LYN—Immune System—HLA-DRB1—psoriatic arthritis	4.82e-05	0.000242	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HLA-DRB1—psoriatic arthritis	4.8e-05	0.000241	CbGpPWpGaD
Vandetanib—FYN—Immune System—HLA-DRB1—psoriatic arthritis	4.75e-05	0.000238	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-B—psoriatic arthritis	4.67e-05	0.000235	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—TNF—psoriatic arthritis	4.43e-05	0.000223	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—TNF—psoriatic arthritis	4.41e-05	0.000222	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TNF—psoriatic arthritis	4.36e-05	0.000219	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NOS2—psoriatic arthritis	4.33e-05	0.000218	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NOS2—psoriatic arthritis	4.29e-05	0.000216	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CRP—psoriatic arthritis	4.28e-05	0.000215	CbGpPWpGaD
Vandetanib—FYN—Disease—NOS2—psoriatic arthritis	4.17e-05	0.00021	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-B—psoriatic arthritis	4.13e-05	0.000208	CbGpPWpGaD
Vandetanib—LCK—Immune System—CRP—psoriatic arthritis	4.13e-05	0.000207	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HLA-DRB1—psoriatic arthritis	4.1e-05	0.000206	CbGpPWpGaD
Vandetanib—LCK—Immune System—HLA-DRB1—psoriatic arthritis	3.95e-05	0.000199	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NOS2—psoriatic arthritis	3.83e-05	0.000192	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TNF—psoriatic arthritis	3.77e-05	0.000189	CbGpPWpGaD
Vandetanib—SRC—Immune System—CRP—psoriatic arthritis	3.65e-05	0.000184	CbGpPWpGaD
Vandetanib—EGFR—Disease—NOS2—psoriatic arthritis	3.61e-05	0.000181	CbGpPWpGaD
Vandetanib—SRC—Immune System—HLA-DRB1—psoriatic arthritis	3.5e-05	0.000176	CbGpPWpGaD
Vandetanib—LCK—Disease—NOS2—psoriatic arthritis	3.47e-05	0.000175	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TNF—psoriatic arthritis	3.22e-05	0.000162	CbGpPWpGaD
Vandetanib—SRC—Disease—NOS2—psoriatic arthritis	3.08e-05	0.000155	CbGpPWpGaD
